Biotest vz. Aktie 325670 / DE0005227235
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
04.08.2025 13:00:04
|
EQS-News: Biotest AG receives a request from Grifols S.A. to convene an extraordinary general meeting
EQS-News: Biotest AG
/ Key word(s): Legal Matter
PRESS RELEASE
Biotest AG receives a request from Grifols S.A. to convene an extraordinary general meeting
Dreieich, 4 August 2025. Biotest AG hereby announces that its majority shareholder, Grifols S.A., Barcelona, Spain, submitted a request to the Management Board on July 31, 2025, initially via electronic communication and subsequently in writing on August 1, 2025, to convene an extraordinary general meeting to resolve on the change of legal form of Biotest AG from a stock corporation (Aktiengesellschaft, AG) into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA). The Supervisory Board was immediately informed of the receipt of this request. According to the proposal, a limited liability company (GmbH), to be renamed Biotest Management GmbH, shall join the company as the general partner with unlimited liability. Following the change of legal form, the company shall operate under the name Biotest GmbH & Co. KGaA. The proposal further provides that shareholders’ participation in Biotest GmbH & Co. KGaA shall correspond to their existing shareholding in Biotest AG at the time of the transformation, and that the preferential rights attached to the preferred shares shall remain unchanged in structure and scope. The Management Board is currently reviewing whether the request submitted by Grifols S.A. meets the requirements set out in Section 122 (1) of the German Stock Corporation Act (AktG) for convening an extraordinary general meeting, and whether it will support the proposed resolution or submit an alternative proposal. Should the request meet the relevant legal requirements, the Management Board will convene an extraordinary general meeting and inform shareholders in due time.
About Biotest Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,500 employees worldwide. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com). Biotest AG will now also be publishing official press releases via X. You can find us at: https://twitter.com/BiotestAG
IR contact Dr Monika Baumann (Buttkereit) Phone: +49-6103-801-4406
PR contact Miriam Oehme Phone: +: +49 -152 07016 992
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Disclaimer
04.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2179022 04.08.2025 CET/CEST
Nachrichten zu Biotest AG Vz.
Let’s talk about Börsenjahr 2025 | Börsentag Zürich 2025
Ein besonderes Highlight des Börsentag Zürich 2025 war die grosse Diskussionsrunde mit:
👉 Thomas B. Kovacs (Sparkojote)
👉 Robert Halver (Baader Bank)
👉 Tim Schäfer (Finanzblogger, New York)
👉 Lars Erichsen (Börsencoach & YouTuber)
👉 David Kunz (COO, BX Swiss)
Gemeinsam analysieren sie die Entwicklungen an den Finanzmärkten 2025, teilen Einschätzungen zu aktuellen Trends und geben spannende Einblicke für Anleger.
📌 Themen im Fokus:
🔹Welche Krisen & geopolitischen Risiken beschäftigen die Märkte wirklich?
🔹Wie wirken sich Zölle speziell auf die Schweiz und ihre Exportwirtschaft aus?
🔹Zinspolitik: Unterschiede zwischen USA, Europa und Schweiz.
🔹Aktien vs. Immobilien: Welche Assetklasse lohnt sich 2025 mehr?
🔹Künstliche Intelligenz – Hype oder langfristiger Wachstumstreiber?
🔹Gold vs. Bitcoin: Welches Asset ist der bessere Schutz im Depot?
🔹Inflation, Liquidität und Notenbanken: Warum Sachwerte profitieren.
🔹Blick in die Glaskugel: Wo stehen Aktien & Krypto Ende 2025?
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI mit freundlichem Wochenauftakt -- DAX unentschlossen -- Asiens Börsen schliessen mehrheitlich festerZum Start in die neue Woche verbucht der heimische Markt kleine Aufschläge, während sich der deutsche Leitindex volatil zeigt. An den Märkten in Fernost ging es unterdessen überwiegend nach oben.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |